Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Reviva Pharmaceuticals raises $30 million for CNS drug development

Published Nov 20, 2023 04:39PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.

Reviva Pharmaceuticals Holdings, Inc., a company dedicated to developing treatments for central nervous system (CNS) diseases, has successfully raised approximately $30 million through a registered direct offering. The funds are earmarked for advancing research and development efforts, particularly the Phase 3 RECOVER-2 trial of brilaroxazine for treating schizophrenia.

The offering involved the sale of around 6 million shares and warrants at a price of $5.125 each to healthcare-focused institutions and an affiliated investment vehicle managed by a board member director. The warrants have a five-year term and an exercise price of $5.00, with immediate exercisability. H.C. Wainwright & Co served as the placement agent for the transaction.

Brilaroxazine, Reviva's leading candidate, has shown statistically significant results in its application against schizophrenia and also holds Orphan Drug Designation by the FDA for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The company has secured composition of matter patents across various jurisdictions to protect its intellectual property.

Investor relations for Reviva are managed by LifeSci Advisors, LLC. Additional information regarding the offering can be accessed through electronic copies available from the SEC or directly from H.C. Wainwright & Co. The capital raised will support R&D projects like the ongoing RECOVER-2 trial and other clinical development programs, including RP1208, as well as general corporate objectives. This includes potential acquisitions or investments in related fields, although there are no immediate plans for such actions.

The funding round comes under a shelf registration statement declared effective on February 2, 2022. Prospectus supplements and related materials detailing this offering have been made available electronically through the SEC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Reviva Pharmaceuticals raises $30 million for CNS drug development
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email